Sales acceleration at MedicureA lot has gone wrong in the last few years, true. But it is not correct to analyse Medicure in a skewed, marginal way as has been done by some commentators. The fourth quarter may have shown evidence of an enormous change to come in 2022: revenues and gross profit in Q4 increased a lot compared to the third quarter. Sales were up from C$4.9 to C$6.8 million; gross profits moved from C$2.9 to C$3.9 million. The main contributor was Zypitamag, of which sales increased from C$0.4 to C$3.8 million.
Q1, to be published in May, may give more evidence of the strength in Zypitamag sales. If so, the shares will go higher.